CTOs on the Move

ARCA biopharma

www.arcabio.com

 
ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA`s lead development program is intended to be a direct implementation of those ideas. Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF). ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted prevention treatment for AF. ARCA is also developing rNAPc2 ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.arcabio.com
  • 10170 Church Ranch Way Suite 100
    Westminster, CO USA 80021
  • Phone: 720.940.2100

Executives

Name Title Contact Details

Similar Companies

GeneGo bioinformatics software

GeneGo bioinformatics software is a Saint Joseph, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Verdezyne

Verdezyne, Inc. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vaxcyte

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte`s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and the XpressCFᵀᴹ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company`s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte`s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of greater than 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.

SignalChem Lifesciences

SignalChem Lifesciences Corporation is a privately owned biopharmaceutical company specializing in the discovery and development of kinase inhibitors as innovative therapies for cancer, inflammation and neurological diseases.   The Company has a robust kinase platform encompassing 450 kinase targets and assays for the development and commercialization of unique therapies in many diseases.   This vast resource empowers SLC’s scientists to identify novel drug candidates against kinase targets of interest.   Another key part of SLC’s kinase drug development platform is KineCore, a kinase focused small molecule library that was designed and assembled in-house.

Cognition Therapeutics

Cognition Therapeutics Inc. is a drug discovery and development company located in Pittsburgh, Pennsylvania. Founded in 2007, the company uses proprietary biology and chemistry platforms to discover novel drug targets and disease modifying therapies for disorders of the central nervous system.